Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Prophage integration into CRISPR loci enables evasion of antiviral immunity in Streptococcus pyogenes

Abstract

CRISPR loci are composed of short DNA repeats separated by sequences, known as spacers, that match the genomes of invaders such as phages and plasmids. Spacers are transcribed and processed to generate RNA guides used by CRISPR-associated nucleases to recognize and destroy the complementary nucleic acids of invaders. To counteract this defence, phages can produce small proteins that inhibit these nucleases, termed anti-CRISPRs (Acrs). Here we demonstrate that the ΦAP1.1 temperate phage utilizes an alternative approach to antagonize the type II-A CRISPR response in Streptococcus pyogenes. Immediately after infection, this phage expresses a small anti-CRISPR protein, AcrIIA23, that prevents Cas9 function, allowing ΦAP1.1 to integrate into the direct repeats of the CRISPR locus, neutralizing immunity. However, acrIIA23 is not transcribed during lysogeny and phage integration/excision cycles can result in the deletion and/or transduction of spacers, enabling a complex modulation of the type II-A CRISPR immune response. A bioinformatic search identified prophages integrated not only in the CRISPR repeats, but also the cas genes, of diverse bacterial species, suggesting that prophage disruption of the CRISPR–cas locus is a recurrent mechanism to counteract immunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ΦAP1.1 lysogenization into the CRISPR locus.
Fig. 2: Disruption of CRISPR function by ΦAP1.1 lysogenization.
Fig. 3: ΦAP1.1 carries a type II-A CRISPR–Cas inhibitor, AcrIIA23.
Fig. 4: AcrIIA23 is not transcribed from ΦAP1.1 prophages.
Fig. 5: ΦAP1.1 mediates the transduction of CRISPR spacers.
Fig. 6: Prophage integration into other CRISPR–cas loci.

Similar content being viewed by others

Data availability

Source data are provided with this paper. The data from this study are available from the corresponding authors upon request. The raw data for the RNA-seq experiments in Figs. 4a,b, 5c,d and the DNA reads of the ΦAP1.1-spec sequence can be found at the Sequence Read Archive (NIH), BioProject accession number PRJNA668016. The sequence of ΦAP1.1-spec is deposited under accession number MW168838. CRISPR–Cas databases were accessed from CRISPRCasFinder and the prophage database was accessed from PHASTER.

Code availability

Custom python scripts are deposited at https://github.com/Marraffini-Lab/Varble_etal_2021.git. Included are scripts that interact with PHASTER to determine CRISPR proximity to prophages (PHASTER_CRISPR.py), search deep sequencing data for spacer sequences in the phage ΦAP1.1 attB site (Phage_attb_II.py) and convert.sam files to.wig files for RNA sequencing analysis (SAM_WIG.py).

References

  1. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712 (2007).

    Article  CAS  PubMed  Google Scholar 

  2. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322, 1843–1845 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Jansen, R., Embden, J. D., Gaastra, W. & Schouls, L. M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43, 1565–1575 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Brouns, S. J. et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960–964 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67–71 (2010).

    Article  CAS  PubMed  Google Scholar 

  6. Makarova, K. S. et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol. 18, 67–83 (2020).

    Article  CAS  PubMed  Google Scholar 

  7. Heler, R. et al. Cas9 specifies functional viral targets during CRISPR–Cas adaptation. Nature 519, 199–202 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Modell, J. W., Jiang, W. & Marraffini, L. A. CRISPR–Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature 544, 101–104 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. McGinn, J. & Marraffini, L. A. CRISPR–Cas systems optimize their immune response by specifying the site of spacer integration. Mol. Cell 64, 616–623 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wright, A. V. & Doudna, J. A. Protecting genome integrity during CRISPR immune adaptation. Nat. Struct. Mol. Biol. 23, 876–883 (2016).

    Article  CAS  PubMed  Google Scholar 

  14. Xiao, Y., Ng, S., Nam, K. H. & Ke, A. How type II CRISPR–Cas establish immunity through Cas1–Cas2-mediated spacer integration. Nature 550, 137–141 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Deveau, H. et al. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J. Bacteriol. 190, 1390–1400 (2008).

    Article  CAS  PubMed  Google Scholar 

  17. Eitzinger, S. et al. Machine learning predicts new anti-CRISPR proteins. Nucleic Acids Res. 48, 4698–4708 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Forsberg, K. J. et al. Functional metagenomics-guided discovery of potent Cas9 inhibitors in the human microbiome. Elife 8, e46540 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hynes, A. P. et al. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9. Nat. Microbiol. 2, 1374–1380 (2017).

    Article  CAS  PubMed  Google Scholar 

  20. Mahendra, C. et al. Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer. Nat. Microbiol. 5, 620–629 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rauch, B. J. et al. Inhibition of CRISPR–Cas9 with bacteriophage proteins. Cell 168, 150–158.e10 (2017).

    Article  CAS  PubMed  Google Scholar 

  22. Uribe, R. V. et al. Discovery and characterization of Cas9 inhibitors disseminated across seven bacterial phyla. Cell Host Microbe 25, 233–241.e5 (2019).

    Article  CAS  PubMed  Google Scholar 

  23. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. & Davidson, A. R. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493, 429–432 (2013).

    Article  CAS  PubMed  Google Scholar 

  24. Stanley, S. Y. et al. Anti-CRISPR-associated proteins are crucial repressors of Anti-CRISPR transcription. Cell 178, 1452–1464.e13 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Birkholz, N., Fagerlund, R. D., Smith, L. M., Jackson, S. A. & Fineran, P. C. The autoregulator Aca2 mediates anti-CRISPR repression. Nucleic Acids Res. 47, 9658–9665 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ferretti, J. J., Stevens, D. L. & Fischetti, V. A. (eds) Streptococcus pyogenes: Basic Biology to Clinical Manifestations (University of Oklahoma Health Sciences Center, 2016).

  27. Fischetti, V. A. In vivo acquisition of prophage in Streptococcus pyogenes. Trends Microbiol. 15, 297–300 (2007).

    Article  CAS  PubMed  Google Scholar 

  28. Howard-Varona, C., Hargreaves, K. R., Abedon, S. T. & Sullivan, M. B. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME J. 11, 1511–1520 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nozawa, T. et al. CRISPR inhibition of prophage acquisition in Streptococcus pyogenes. PLoS ONE 6, e19543 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yamada, S. et al. Phylogenetic relationship of prophages is affected by CRISPR selection in Group A Streptococcus. BMC Microbiol. 19, 24 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fiebig, A. et al. Comparative genomics of Streptococcus pyogenes M1 isolates differing in virulence and propensity to cause systemic infection in mice. Int. J. Med. Microbiol. 305, 532–543 (2015).

    Article  CAS  PubMed  Google Scholar 

  32. Kjems, E. Studies on streptococcal bacteriophages. 2. Adsorption, lysogenization, and one-step growth experiments. Acta Pathol. Microbiol. Scand. 42, 56–66 (1958).

    Article  CAS  PubMed  Google Scholar 

  33. Euler, C. W. et al. Targeted curing of all lysogenic bacteriophage from Streptococcus pyogenes using a novel counter-selection technique. PLoS ONE 11, e0146408 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Desiere, F., McShan, W. M., van Sinderen, D., Ferretti, J. J. & Brussow, H. Comparative genomics reveals close genetic relationships between phages from dairy bacteria and pathogenic Streptococci: evolutionary implications for prophage–host interactions. Virology 288, 325–341 (2001).

    Article  CAS  PubMed  Google Scholar 

  35. Meeske, A. J. et al. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR–Cas immunity. Science 369, 54–59 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bondy-Denomy, J. et al. A unified resource for tracking Anti-CRISPR names. CRISPR J. 1, 304–305 (2018).

    Article  PubMed  Google Scholar 

  37. Perez-Casal, J., Caparon, M. G. & Scott, J. R. Mry, a trans-acting positive regulator of the M protein gene of Streptococcus pyogenes with similarity to the receptor proteins of two-component regulatory systems. J. Bacteriol. 173, 2617–2624 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nussenzweig, P. M., McGinn, J. & Marraffini, L. A. Cas9 cleavage of viral genomes primes the acquisition of new immunological memories. Cell Host Microbe 26, 515–526.e6 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Feiner, R. et al. A new perspective on lysogeny: prophages as active regulatory switches of bacteria. Nat. Rev. Microbiol. 13, 641–650 (2015).

    Article  CAS  PubMed  Google Scholar 

  40. Shapiro, J. A. Molecular model for the transposition and replication of bacteriophage Mu and other transposable elements. Proc. Natl Acad. Sci. USA 76, 1933–1937 (1979).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Taylor, A. L. Bacteriophage-induced mutation in Escherichia coli. Proc. Natl Acad. Sci. USA 50, 1043–1051 (1963).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Davidson, A. R. et al. Anti-CRISPRs: protein inhibitors of CRISPR–Cas systems. Annu. Rev. Biochem. 89, 309–332 (2020).

    Article  CAS  PubMed  Google Scholar 

  43. Banks, D. J., Beres, S. B. & Musser, J. M. The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence. Trends Microbiol. 10, 515–521 (2002).

    Article  CAS  PubMed  Google Scholar 

  44. McShan, W. M., McCullor, K. A. & Nguyen, S. V. The bacteriophages of Streptococcus pyogenes. Microbiol Spectr. 7, 7.3.8 (2019).

  45. Osuna, B. A. et al. Critical anti-CRISPR locus repression by a bi-functional Cas9 inhibitor. Cell Host Microbe 28, 23–30.e5 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Marino, N. D. et al. Discovery of widespread type I and type V CRISPR-Cas inhibitors. Science 362, 240–242 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Yin, Y., Yang, B. & Entwistle, S. Bioinformatics identification of anti-CRISPR loci by using homology, guilt-by-association, and CRISPR self-targeting spacer approaches. mSystems 4, e00455-19 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Osuna, B. A. et al. Listeria phages induce Cas9 degradation to protect lysogenic genomes. Cell Host Microbe 28, 31–40.e9 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Varble, A., Meaden, S., Barrangou, R., Westra, E. R. & Marraffini, L. A. Recombination between phages and CRISPR-cas loci facilitates horizontal gene transfer in staphylococci. Nat. Microbiol. 4, 956–963 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bankevich, A. et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 19, 455–477 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Garneau, J. R., Depardieu, F., Fortier, L. C., Bikard, D. & Monot, M. PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Sci. Rep. 7, 8292 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Nelson, D., Schuch, R., Chahales, P., Zhu, S. & Fischetti, V. A. PlyC: a multimeric bacteriophage lysin. Proc. Natl Acad. Sci. USA 103, 10765–10770 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Goldberg, G. W., Jiang, W., Bikard, D. & Marraffini, L. A. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting. Nature 514, 633–637 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kreiswirth, B. N. et al. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305, 709–712 (1983).

    Article  CAS  PubMed  Google Scholar 

  55. Pall, G. S. & Hamilton, A. J. Improved northern blot method for enhanced detection of small RNA. Nat. Protoc. 3, 1077–1084 (2008).

    Article  CAS  PubMed  Google Scholar 

  56. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Couvin, D. et al. CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins. Nucleic Acids Res. 46, W246–W251 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Arndt, D. et al. PHASTER: a better, faster version of the PHAST phage search tool. Nucleic Acids Res. 44, W16–W21 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zimmermann, L. et al. A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its core. J. Mol. Biol. 430, 2237–2243 (2018).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank A. J. Meeske for bioinformatic assistance with the RNA-seq analysis. Support for this work was provided by the National Institutes of Health Director’s Pioneer Award 1DP1GM128184-01 and the Burroughs Wellcome Fund PATH Award to L.A.M. L.A.M. is an Investigator of the Howard Hughes Medical Institute. A.V. was supported by the Arnold and Mabel Beckman Postdoctoral Fellowship. J.T.R. was supported by the Boehringer Ingelheim Fonds PhD fellowship. Funding for V.A.F. and E.C. was from the Rockefeller University Laboratory Support. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author information

Authors and Affiliations

Authors

Contributions

A.V. and L.A.M. conceived the study. E.C., C.W.E. and V.A.F. aided with experimental design. A.V. performed all the experiments with the help of J.F. and A.K. E.C. and P.M. assisted with bioinformatic analysis. E.C. and C.W.E. provided assistance, strains and reagents for S. pyogenes experiments. J.T.R. provided reagents. A.V. and L.A.M. wrote the manuscript with the help of the other authors.

Corresponding authors

Correspondence to Andrew Varble or Luciano A. Marraffini.

Ethics declarations

Competing interests

L.A.M. and A.V. are co-inventors on a patent application filed by The Rockefeller University relating to work in this study. L.A.M. is a founder and advisor of Intellia Therapeutics, Eligo Biosciences and CRISPR Biotechnologies. The remaining authors declare no competing interests.

Additional information

Peer review information Nature Microbiology thanks Joseph Bondy-Denomy and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 ΦAP1.1 integration into S. pyogenes type II-A CRISPR loci.

(a) ΦAP1.1-like phages integrated into the type II-A CRISPR locus of S. pyogenes strains. (b) Schematic of the ΦAP1.1 genome. Targets for the spacers found in different strains are shown on top or bottom depending on the phage DNA strand that is targeted. The acr region and its four ORFs are highlighted in grey. The aadA gene inserted to confer spectinomycin resistance to ΦAP1.1 lysogens is shown in light blue. (c) Spacer duplication events observed in S. pyogenes K56(ΦAP1.1) lysogens. (d) To determine if the tyrosine site-specific recombinase present in the ΦAP1.1 genome is required for its insertion into the CRISPR repeats, we deleted the integrase gene, generating ΦAP1.1Δint. We infected streptococci with both wild-type and int phages and enumerated spectinomycin-resistant colonies. Interestingly, the number of colony-forming units (cfu) obtained was similar for both infections. However, in the absence of the integrase, the colonies lost antibiotic resistance over time, and we were unable to detect PCR products for the attL site or the phage itself, indicating that infection resulted in the transient transfer of antibiotic resistance but failed to produce lysogenic integration into the CRISPR array. Enumeration of spectinomycin-resistant cfu per ml of S. pyogenes CEMΔΦ[Δ2-5] cultures infected with either wild-type ΦAP1.1 or ΦAP1.1Δint. Mean + STD of 3 biological replicates are reported. Interestingly, the number of colony-forming units (cfu) obtained was similar for both infections. However, in the absence of the integrase, the colonies lost antibiotic resistance over time (not shown). (e) Agarose gel electrophoresis of the attL PCR product obtained after the amplification shown in Fig. 1B, using DNA extracted from 24 spectinomycin-resistant colonies that resulted from infection of S. pyogenes CEMΔΦ[Δ2-5] cultures with ΦAP1.1Δint. Collected from three biological replicates. (f) Sequences of the S. pyogenes CEM1ΔΦ spc4 crRNA annealed to its targets in ΦAP1.1 and ΦAP1.1ΔacrIIA23-esc. The PAM nucleotides are boxed. The escape mutation of ΦAP1.1ΔacrIIA23-esc is in red. (g) Base pairs formed between the crRNA and tracrRNA of S. pyogenes (grey dots). Blue sequence, spacer; pink sequence, repeat; black sequence, tracrRNA. Black arrows indicate RNase III cleavage sites required for crRNA processing. (h) Same as (G) but showing the possible base pairs formed by the prophage transcript and the tracrRNA. Lack of annealing with the prophage-derived sequences (orange) prevents RNase III cleavage and thus processing of the upstream crRNA.

Source data

Extended Data Fig. 2 ΦAP1.1 lysogenization location.

We decided to look for integration of ΦAP1.1 in other genomic sites with the 8-bp sequence of the attB present on the CRISPR repeat. Because strain K56 is not sequenced and therefore we could not identify such sequences, we decided to perform experiments with strain SF370, which harbors an additional 27 sites with the attB sequence. To do this, we infected strain CEM1ΔΦ[Δ2-5], which lacks the prophages as well as most spacers of the CRISPR array (in particular spc4, which targets ΦAP1.1) present in SF370. We isolated and analyzed 110 spectinomycin-resistant colonies and looked for the presence of the phage (p) and its integration attL site (i) via PCR. We found that all prophages were inserted into the CRISPR array (in different repeats, generating different sizes for the attL PCR products). This result indicates a strong preference for integration into the repeat sequences and also suggests that regions outside of the 8-bp attB site are important for integration. Agarose gel electrophoresis of the attL (i) or phage (p) PCR products obtained after selection of individual spectinomycin-resistant ΦAP1.1 lysogens. PCRs for individual lysogens are divided by black lines.

Source data

Extended Data Fig. 3 ΦAP1.1 lysogenization into the S. pyogenes NCTC13743 type II-A CRISPR locus.

(a) S. pyogenes NCTC13743 type II-A CRISPR-cas locus, wild-type and the mutant lacking spacer-repeat units 1 through 10, [Δ1-10]. The ‘t’ indicates three degenerate repeats that contain mutations from the repeat consensus sequence. (b) Sequences of the S. pyogenes NCTC13743 spc2, spc6 and spc9 crRNAs annealed to their targets in ΦAP1.1. The PAM nucleotides are boxed. (c) We verified that the type II-A CRISPR system present in NCTC13743 is capable of restricting a plasmid containing the ΦAP1.1 target sties. Transformation efficiency of the pC194 plasmid or a modified version harboring the three targets for spc2, spc6 and spc9, pTgt2-6-9 from ΦAP1.1, after electroporation of wild-type or [Δ1-10] S. pyogenes NCTC13743 competent cells. Mean + STD of 3 biological replicates are reported. These results demonstrate that the type II-A CRISPR system present in this strain is capable of restricting a plasmid containing the three target sequences present in ΦAP1.1 (d) Diagrams of the type II-A locus of 25 ΦAP1.1 lysogens in S. pyogenes NCTC13743, reconstructed after sequencing of their attL and attR sites.

Source data

Extended Data Fig. 4 AcrIIA23 inhibits the type II-A CRISPR-Cas response in S. pyogenes NCTC13743 and S. aureus RN4220.

(a) Lysogenization rates of ΦAP1.1 or ΦAP1.1ΔacrIIA23 after infection of wild-type or [Δ1-10] S. pyogenes NCTC13743 cells. Mean + STD of 3 biological replicates are reported. (b) Integration of the S. pyogenes CEM1ΔΦ type II-A system into the lipase gene of S. aureus RNA4220 using the integrative vector pCL55, generating strain JAV17. A CRISPR locus with a spacer matching the gp68 gene from the virulent staphylococcal phage ΦNM4γ4 was also integrated, generating JAV16. (c) JAV17 and JAV16 strains were transformed with each of the individual ΦAP1.1 ORFs under the control of an anhydrotetracycline (aTc)-inducible promoter, on the pJTR162 staphylococcal plasmid backbone, with the exception of ORF3, for which we did not obtain transformants. Strains harboring the pJTR-ORF1, pJTR-ORF2 and pJTR-ORF4 constructs were then infected with ΦNM4γ4 in the presence or absence of aTc, and pfus were counted. We found that none of the ORFs affected the immunity of the JAV16 strain in the absence of the inducer, and ΦNM4γ4 propagation was limited. In the presence of aTc, however, ORF2 expression enabled high levels of viral replication, similar to those observed in the absence of type II-A CRISPR-Cas immunity after infection of the JAV17 strain. Efficiency of plaquing of phage ΦNM4γ4 on soft agar lawns of S. aureus JAV17 or JAV16, in the presence or absence of aTc, carrying the pJTR162 control plasmid or versions that express the different ORFs of the ΦAP1.1 anti-CRISPR locus. Mean + STD of 3 biological replicates are reported. Two-tailed unpaired t-test was used to calculate P value.

Source data

Extended Data Fig. 5 ΦAP1.1ΔacrIIA23-esc integration pattern.

(a) Frequency of ΦAP1.1ΔacrIIA23-esc lysogens (n = 50) carrying attL or attR sites in each of the DRs of the CEM1ΔΦ CRISPR locus. (b) Same as (A) but showing the combined distribution of attL or attR sites. (c) Northern blot analysis of spc4 crRNAs, as well as 5 S rRNA, produced by wild-type S. pyogenes CEM1ΔΦ or its different ΦAP1.1 (DR1-5, 1-t) or ΦAP1.1ΔacrIIA23-esc (DR6, DRt) lysogens. (d) Transformation efficiency of the pC194 plasmid or a modified version harboring a target for spc4 from ΦAP1.1, pTgt4, after electroporation of the strains used in (C). Mean + STD of 3 biological replicates are reported.

Source data

Extended Data Fig. 6 ΦAP1.1-mediated transduction of spacers from the CEM1ΔΦ to the K56 CRISPR locus.

(a) Agarose gel electrophoresis of the attL or attR PCR products obtained after treatment of S. pyogenes CEM1ΔΦ(ΦAP1.1::DR5) lysogens with mitomycin C (MMC). Primers used and the expected products are shown in the diagrams to the right. Black arrowheads indicate PCR products that lack a number of the expected spacer-repeat units. Representative of three independent replicates. (b) Example of aberrant ΦAP1.1 excision in S. pyogenes CEM1ΔΦ(ΦAP1.1::DR3) lysogens, where DR1 or DR2 are used instead of attL for recombination with attR. ΦAP1.1-, spc1- and spc2-specific primers used to detect attP sites containing either of these spacers are shown as orange, red and yellow arrows, respectively. (c) Same as (B) but for a ΦAP1.1::DR5 lysogen. (d) Agarose gel electrophoresis of PCR products obtained after the amplification of the attP site of ΦAP1.1 phages induced with MMC from ΦAP1.1::DR3, ΦAP1.1::DR5 and ΦAP1.1::DR1-t lysogens, using spc1-specific primers. (e) Same as (D) but using spc2-specific primers. In both cases we found PCR products that indicated the presence of spacer-repeat units in the DNA of the viral particles, with the intensity of the amplicons indicating more spc1- than spc2-containing viral particles. These results suggest a possible preference for certain excision products. (f) Example of possible recombination of the 5’ end (top) or 3’ end (bottom) attP site of the ΦAP1.1spc1-2 phage with the three attB sites present in the DR1, DR2 and DRt of S. pyogenes K56.

Source data

Extended Data Fig. 7 Spacers targeting prophages integrated into other CRISPR-cas loci.

Alignment of spacers described in Fig. 6 with their phage target sites; in the 5’ to 3’ orientation.

Supplementary information

Supplementary Information

Supplementary Tables 1–4 and synthetic DNA.

Reporting Summary.

Source data

Source Data Fig. 1

Original unprocessed DNA gel images.

Source Data Fig. 1

Raw numerical data.

Source Data Fig. 2

Original unprocessed northern blot images.

Source Data Fig. 2

Raw numerical data.

Source Data Fig. 3

Raw numerical data.

Source Data Fig. 5

Original unprocessed DNA gel images.

Source Data Fig. 5

Raw numerical data.

Source Data Extended Data Fig. 1

Original unprocessed DNA gel images.

Source Data Extended Data Fig. 1

Raw numerical data.

Source Data Extended Data Fig. 2

Original unprocessed DNA gel images.

Source Data Extended Data Fig. 3

Raw numerical data.

Source Data Extended Data Fig. 4

Raw numerical data.

Source Data Extended Data Fig. 5

Original unprocessed northern blot images.

Source Data Extended Data Fig. 5

Raw numerical data.

Source Data Extended Data Fig. 6

Original unprocessed DNA gel images.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varble, A., Campisi, E., Euler, C.W. et al. Prophage integration into CRISPR loci enables evasion of antiviral immunity in Streptococcus pyogenes. Nat Microbiol 6, 1516–1525 (2021). https://doi.org/10.1038/s41564-021-00996-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41564-021-00996-8

This article is cited by

Search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology